Companies › Soleno Therapeutics
1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Metabolic and endocrine, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Diazoxide Potassium channel, inwardly rectifying, subfamily J, member 11 opener; Potassium channel, inwardly rectifying, subfamily J, member 8 opener | Ion channels | Phase 3 | Prader-Willi Syndrome; Diabetes Mellitus; Hyperinsulinemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05701774 | Diazoxide | Phase 3 | Prader-Willi Syndrome | Other | Jan 2026 |
| NCT03540758 | Diazoxide | Phase 2 | Diabetes Mellitus | Metabolic and endocrine | Apr 2027 |
| NCT07403604 | Diazoxide | Phase 1 | Hyperinsulinemia | Metabolic and endocrine | Sep 2029 |
LXO Ireland Biotechnology Institute IMASD Energenesis Biomedical Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.